# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001654954-25-009886
**Filing Date:** 2025-8
**Character Count:** 5487
**Document Hash:** 09a261f61f33b96a0da9fdbcb258cf55
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-25-009886.hdr.sgml**: 20250821

**ACCESSION NUMBER**: 0001654954-25-009886

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250821

**FILED AS OF DATE**: 20250821

**DATE AS OF CHANGE**: 20250821

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 251239151

**BUSINESS ADDRESS:**
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** WC1A 1DG
- **BUSINESS PHONE:** 011442080475000

**MAIL ADDRESS:**
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** WC1A 1DG

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **Form 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of August 2025

Commission File Number 001-15170

 **GSK plc**

(Translation of registrant's name into English)

 **79 New Oxford Street, London, WC1A 1DG**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the '**Company**')

Transaction notification

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **1.**<br>| **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; a)<br>| Name | Shobie Ramakrishnan | Shobie Ramakrishnan |
| &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; b)<br>| Position/status | Chief Digital and Technology Officer | Chief Digital and Technology Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment<br>| Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name<br>| GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI<br>| 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | American Depositary Shares ('ADSs')<br>ISIN: US37733W2044 | American Depositary Shares ('ADSs')<br>ISIN: US37733W2044 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Following the vesting on 19 August 2025 of 25% of an award made on 19 August 2019 under the GlaxoSmithKline Deferred Investment Award Programme, Ms Ramakrishnan will receive a cash payment of $99,122.98 less applicable tax withholding in respect of 2,501.842 notional ADSs. | Following the vesting on 19 August 2025 of 25% of an award made on 19 August 2019 under the GlaxoSmithKline Deferred Investment Award Programme, Ms Ramakrishnan will receive a cash payment of $99,122.98 less applicable tax withholding in respect of 2,501.842 notional ADSs. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | $39.6200<br>| 2501.842 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction<br>| 2025-08-19 | 2025-08-19 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| N/A | N/A |

---

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

---

| | |
|:---|:---|
|  | **GSK plc** |
|  | (Registrant) |
| Date: August 21, 2025 |  |
|  | By:/s/ VICTORIA WHYTE<br> -------------------------- |
|  | Victoria Whyte |
|  | Authorised Signatory for and on |
|  | behalf of GSK plc |

---